Rapamycin (Sirolimus)

Pfizer辉瑞授权 目录号:S1039 别名: AY 22989,NSC-2260804

Rapamycin (Sirolimus) Chemical Structure

Molecular Weight(MW): 914.18

Rapamycin (Sirolimus)是一种特定的 mTOR 抑制剂,在 HEK293细胞中,IC50 为 ~0.1 nM。

规格 价格 库存 购买数量  
RMB 2501.99 现货
RMB 580.39 现货
RMB 2216.87 现货
RMB 5501.68 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户购买Selleck的此次产品后发表的文献64篇:

客户使用该产品的13个实验数据:

  • Protein blots showing MYC expression in naive and persister cells after 3 d of treatment with 2 uM AKT inhibitor MK-2206 (AKTi) or 10 nM mTOR inhibitor rapamycin (Rapa).

    Nat Genet 2014 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck.

    Cooperative Effects of AR and mTOR Inhibition In Vitro and In Vivo (A) In vitro response of Pten null;Ar+ murine (CaP8) and human (LNCaP) prostate cancer cells to AR knockdown (sh-AR) or pharmacological inhibition of AR (MDV3100, 10 nM) with and without rapamycin (R: 1 nM) treatment (Sc, control sh oligo). (B and D) In vivo response to treatments with castration, MDV3100, rapamycin, or their combinations as measured by cell proliferation (Ki67+cells) and (C and D) tumor burden in Pb-Cre+;-PtenL/L and Pb-Cre+;PtenL/L:ArL/Y mutants. Scale bars represent 2 mm (C), 200 mm (D), and 75 mm (D, inset). Error bars represent mean ±SD.

    Cancer Cell 2011 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck.

  • 48 hours after addition of rapamycin(150 nM), the cells were imaged as described in Figure A to detect formation of punctuated GFP-LC3 structure. Quantification represented the ratio of GFP-LC3 punctuated positive cell to the total cell counted(Figure B).

    Cell Res 2012 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck.

    H4-LC3-GFP cells were treated with 1 nM IFNA2 for the indicated periods in the presence of 200 nM rapamycin. Images of the cells were collected using an ArrayScan HCS 4.0 Reader. Representative cells are shown. The average spot intensity in 500 cells from each indicated sample was determined. Data are displayed as means ?SD of the spot intensity per cell (below). RLU, relative leight unit.

    Autophagy 2015 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck.

  • Rheb Induces Phospho-eIF2a Independent of mTORC1 and Promotes Phospho-eIF2a Predominantly through PERK (A) Western blotting of indicated proteins of HEK293 expressing cDNAs of myc (control) or myc-Rheb WT were grown in DMEM with serum (+) or without serum (-) or pretreated with the inhibitors rapamycin (250 nM) or DMSO (0.5%, control). (B) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with rapamycin or DMSO as in (A). (C) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with inhibitors of MAPK (PD98059, 50 mM) or PI3K (wortmannin, 100 nM), rapamycin, or DMSO.

    Cell Rep 2015 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck.

    Cells were cultured with the indicated concentrations of PLS-123, rapamycin (Granta519 0.002 μM, Mino 0.001 μM, Z138 0.005 μM), and their combination for 48 h. The results are expressed as the mean of relative activity and S.D. from triplicate cultures. The results are representative of at least three similar experiments.

    Int J Cancer, 2018, 142(1):202-213. Rapamycin (Sirolimus) purchased from Selleck.

  • Autophagy induced by PL-0N and PL may restrict LPS-induced inflammatory responses in RAW264.7 cells. LPS induced autophagy in RAW264.7 cells. Cells were incubated with 1 mM 3-MA or 10 uM Rapamycin in the absence or presence of LPS (1 ug/mL) for 16 h. Then immunofluorescence for LC3 was visualized using a Zeiss LSM 710 confocal microscope.

    Biochem Pharmacol 2015 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck.

    Inhibition of mTOR activity may be responsible for sorafenib-induced down-regulation of survivin. H1299 cells were treated with the indicated concentration of RAD001 or Rapamycin for 48 h. Then H1299 cells were incubated with or without 5 μM sorafenib, with or without 5 μM RAD001, and with or without 2 μM rapamycin for 48 h.  The indicated protein levels were determined by Western blot analysis. β-Actin protein levels were measured as loading controls.

     

     

    Biochem Pharmacol 2011 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck.

  • Rapamycin (RPM) inhibits OA-induced lipogenesis. Male SD rats were divided into three groups, and then treated as follows for seven days: group I (control; Ctrl), normal diet + vehicle; group II (OA), 1% OA diet + vehicle; group III (OA + RPM), 1% OA diet + RPM. (A) Hepatic TG concentrations were determined using the serum triglyceride determination kit. (B) Fixed liver sections were subjected to HE and Oil Red O staining as well as immunohistochemistry assays with SREBP-1 antibody. Representative microphotographs of liver specimens from all groups of rats are shown. (C) The levels of mRNA of the indicated genes involved in lipogenesis were determined by real-time PCR. Each bar represents the mean ±SE of the results obtained from six rats. * P < 0.05, ** P < 0.01, *** P < 0.001.

    J Lipid Res 2011 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck.

    Immunophilins participate in SOCE activation by CN-dependent but also CN-independent signaling pathways. Fura-2 loaded platelets were suspended in HBS and subsequently incubated at 37oC for 30 min with rapamycin (500 nM). Once incubation time was over, platelets were stimulated with TG (200 nM) in a calcium free-HBS (EGTA 100 μM was added as indicated the by arrowhead) and 4 min later CaCl2 (300 µM) was added to visualized calcium entry. Changes in fura-2 fluorescence were monitored using the 340/380nm ratio and calibrated in terms of [Ca2+]c . Traces are representative of four to six independent experiments. *,**, *** represents p < 0.05, p < 0.01 and p <0.001, respect control platelets.

    Biochim Biophys Acta 2013 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck.

  • Tuberc Respir Dis 2013 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck.

    Rapamycin inhibits growth-dependent TCTP induction. Cells were serum-starved for 24h and restimulated with 20% FBS for the indicated times in the presence or absence of rapamycin. The graph shows the relative TCTP signal, corrected for the loading control.

    2011 Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck.

  • 2013 Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck.

产品安全说明书

mTOR抑制剂选择性比较

生物活性

产品描述 Rapamycin (Sirolimus)是一种特定的 mTOR 抑制剂,在 HEK293细胞中,IC50 为 ~0.1 nM。
靶点
mTOR [1]
(HEK293 cells)
~0.1 nM
体外研究

Rapamycin作用于HEK293细胞,抑制内源性mTOR活性,IC50为~0.1 nM,而iRap和AP21967 作用时,IC50分别为~5 nM 和~10 nM。[1] Rapamycin处理酿酒酵母,诱导细胞周期停在G1/S期,且抑制翻译。[2] Rapamycin显著抑制T98G和U87-MG细胞活力,这种作用具有剂量依赖性,IC50分别为2 nM和 1 μM, 而对U373-MG细胞没有作用活性,IC50>25 μM。Rapamycin(100 nM) 作用于对Rapamycin敏感的U87-MG和T98G细胞,通过抑制mTOR功能,而诱导细胞周期停在G1期,也诱导自噬而不是凋亡。[6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 NETEcYJEgXSxdH;4bYMhSXO|YYm= MmnxNVAhdk1? MWS3NkBp NXLLfY13TE2VTx?= NX;Vbm9{WG:2ZX70bYF1\XNiY3HtdJRwfGinY3nuMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 MkW5NlQ6ODB6N{O=
HT-29 NHiyVJREgXSxdH;4bYMhSXO|YYm= NHrnXlYyOCCwTR?= MUe3NkBp NVP1XI1nTE2VTx?= MlnGVI91\W62aXH0[ZMh\GmpaYTvfIlvNWmwZIXj[YQh[3m2b4TvfIlkcXS7 M{CyRlI1QTByOEez
HT-29 MmDPR5l1d3SxeHnjJGF{e2G7 MWOxNEBvVQ>? MYC3NkBp MYnEUXNQ NULNVoRmWG:2ZX70bYF1\XNiNT3mcJVwem:3cnHjbYwucW6mdXPl[EBkgXSxdH;4bYNqfHl? MWGyOFkxODh5Mx?=
PC3 MoXnT4lv[XOnIFHzd4F6 MoXhNVAxKG6P NGTLcIIyKGh? M3r5bGROW09? M4HrWHBwfGWwdHz5JIlvcGmkaYTzJI1VV1JvbXXkbYF1\WRiU{[gdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kA9OTBibl2u MoTzNlE6Pzh4OEO=
PC3 M2fzRWtqdmG|ZTDBd5NigQ>? NVTG[4ZTOTByIH7N NEnJV44yKGh? MWDEUXNQ NWTaOlc3TG:nczDuc5QhcW6qaXLpeEBuXE:ULX3l[IlifGWmIFHreEBxcG:|cHjvdplt[XSrb36= MofRNlE6Pzh4OEO=
PC3 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M121NFEvPSEQvF2= NVfpSlA{OSCq M{i2cmROW09? NHLFWGJKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFOzJINmdGy|IIfpeIghUUN3MDDv[kA9OTBibl2= NU\je4tWOjF7N{i2PFM>
HEK293 M2XaVmZ2dmO2aX;uJGF{e2G7 MX6xNFAhdk1? MnjmPEBp NGrRbXRFVVOR NF3kUlRKdmirYnn0d{BVWEFvaX7keYNm\CCmZXfyZYRifGmxbjDv[kBR\GOmNDD3bZRpKEWFNUCgc4YhPTBibl2= NH3mdZozOTV|OUOwNS=>
BT-20 M1H2b2tqdmG|ZTDBd5NigQ>? M4jWeFIxKM7:TR?= NX3RNXlITE2VTx?= MVrEc4V{KG6xdDDpcohq[mm2IH3UU3JEOiCmZYDlcoRmdnRicFHrWEBUPDd|IIDoc5NxcG:{eXzheIlwdg>? MVyyNVM2OzV3MR?=
U937 NFfZbpNCdnSrYnHjeIVzcWGuIFHzd4F6 NXrmeY0xPTBizszN MoLFOFghcA>? M2XUdWROW09? NET3PXZKdmS3Y3XzJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCC5aXzkJJR6eGViTHXnbY9v\WyuYTDwcoV2dW:yaHnsZUBRcGmuYXTlcJBpcWFvMTDKVlMzKGmwIGW5N|ch[2WubIO= Mmn1NlEyPDJzME[=
U937 NX\Yb|luSW62aXLhZ5RmemmjbDDBd5NigQ>? MWW1NEDPxE1? NWD1VFBHPDhiaB?= MUXEUXNQ MmXCSI9meyCwb4SgbY5lfWOnIHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEBOUVBicILveIVqdi2mZX\pZ4lmdnRiTHXnbY9v\WyuYTDwcoV2dW:yaHnsZUBLWjN{LUKgbY4hXTl|NzDj[Yxtew>? MXOyNVE1OjFyNh?=
U937 NWjKfVM6SW62aXLhZ5RmemmjbDDBd5NigQ>? NHTXR242OCEQvF2= NU\t[nhXPDhiaB?= NVHMXFJ3TE2VTx?= M4KyT2Rw\XNibn;0JIlv\HWlZTDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5QhTXOlaHXybYNpcWFiY3;sbUBJSjFyMTDpckBWQTN5IHPlcIx{ NYOxTYhROjFzNEKxNFY>
MCF-7 MWDBeZRweGijZ4mgRZN{[Xl? MlTrN|Ahdk1? NV;SeVZmPCCq MUTEUXNQ M1WwPGlv\HWlZYOgZZV1d3CqYXf5 M2jEclIxODJ6MUO0
U87MG MoT3T4lv[XOnIFHzd4F6 M1;IN|Eh|ryP NVrINo1uPiCq NELmV|RFVVOR M{fzSnBwfGWwdHz5JIlvcGmkaYTzJI1VV1JvbXXkbYF1\WRiU{[gdIhwe3Cqb4L5cIF1cW:w NXnnW3lROTl6NEi0NFQ>
U87MG MWrLbY5ie2ViQYPzZZk> NWnvSnlGOSEQvF2= MXK2JIg> M{DE[GROW09? MWPQc5RmdnSueTDpcohq[mm2czC0SWJROSiWN{CpJJBpd3OyaH;yfYxifGmxbh?= NFTGV2gyQTh2OESwOC=>
U87MG M120XWtqdmG|ZTDBd5NigQ>? M{WyNVEh|ryP Mkm0OkBp MWDEUXNQ MUDEc4V{KG6xdDDpcohq[mm2IH3UU3IudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? NYC4SYNtOTl6NEi0NFQ>
U87MG M2XhVmtqdmG|ZTDBd5NigQ>? NVzkfJRpOSEQvF2= MkLyOkBp NWn0TlJHTE2VTx?= NXzwVGZTTG:nczDuc5QhcW6qaXLpeEBRNTSHQmCxLHQ{Py92NjmgdIhwe3Cqb4L5cIF1cW:w NUjGVppGOTl6NEi0NFQ>
COS7 cells expressing EGFP-HDQ74/rheb M2ix[WF2fG:yaHHnfUBCe3OjeR?= MVqwMlIh|ryP MoHJNlQhcA>? NEC3OVBFVVOR MUDJcoR2[2W|IHH1eI9xcGGpeR?= M1\COVE5OzlzOUS5
COS7 cells expressing EGFP-LC3 M13pTGF2fG:yaHHnfUBCe3OjeR?= MWiwMlIh|ryP NV3sVZF7OjRiaB?= NEOzTZVFVVOR Mnj2TY5lfWOnczDheZRweGijZ4m= M1;McFE5OzlzOUS5
H4 NHnafpZHfW6ldHnvckBCe3OjeR?= MXuwMlIh|ryP MmDtNlQhcA>? NETzXoVFVVOR NHezcGFKdmO{ZXHz[ZMhfGinIILheIlwKG:oIHzp[4h1KGOqYXnuJFMhe3WkdX7peEAzKHSxIHzp[4h1KGOqYXnuJFMhe3WkdX7peEAyKGmwIHj1cYFvKEh2IHPlcIx{ MXmxPFAzPDV6NB?=
HeLa NWTpb5d5TnWwY4Tpc44hSXO|YYm= MV6xNFAhdk1? NEDjSIw{PiCq MoLCSG1UVw>? NGrTO29KdmS3Y3XzJGZTSiCNMkC5OXAtKFR{MEm4UEwhXzJzMEHGJI12fGGwdD31ZolyfWm2aX7DJIlvfGW{YXP0bY9v NH7HbXEyPzV4M{O4OS=>
HeLa NY\QNIY3TnWwY4Tpc44hSXO|YYm= NGHIS3EyODBibl2= NVfhbm9xOzZiaB?= NXfhd4R{TE2VTx?= NUjLcXdQUW6mdXPld{BHWkJiV{KxNFFHKG23dHHueE12[mmzdXn0bY5EKGmwdHXyZYN1cW:w MnjPNVc2PjN|OEW=
HeLa Mn\4SpVv[3Srb36gRZN{[Xl? NVzYRXlGOTByIH7N M3r5[FM3KGh? MWrEUXNQ NGjpWJZKdmS3Y3XzJGZTSi2IS1LQJINwdXCuZYigbY51\XKjY4Tpc44> MYqxO|U3OzN6NR?=
SYF M2W2cmZ2dmO2aX;uJGF{e2G7 M{TLW|ExOCCwTR?= MVOyOEBp M{S4S2ROW09? M3;ZfWlv\HWlZYOgSnJDNU[NQmCgZ49ueGyneDDpcpRmemGldHnvci=> NHXtRoQyPzV4M{O4OS=>
SYF MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\3NVAxKG6P MoS2NlQhcA>? MnzOSG1UVw>? NEHhTolKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgV3lHKGOnbHzz MUixO|U3OzN6NR?=
HEK293T NU[2TGtLSW62aY\pdoFtKEG|c3H5 NH3JS|EyKG6P MWi0JIQ> MXXEUXNQ NXPkWos1UW6mdXPld{BidnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIGK1JJdqfGhiRVO1NEBw\iByLkGgcm0> NFXt[HYyPzR6NUWwNS=>
HEK293T M3PIO2FvfGm4aYLhcEBCe3OjeR?= NFTkNHkyKG6P M2fleVQh\A>? M3fteWROW09? MoH5TY5lfWOnczDhcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDITXYyKFh2IIfpeIghTUN3MDDv[kAxNjNibl2= NYrkT2VwOTd2OEW1NFE>
PBMC MYjGeY5kfGmxbjDBd5NigQ>? M1zMW|Ehdk1? NF7KNHkyPCCm MWPEUXNQ M1vqXHJm\HWlZYOgR2NTPSCmZX7zbZR6 NYfyR2kzOTd2OEW1NFE>
PBMC MmLQSpVv[3Srb36gRZN{[Xl? MkPzNUBvVQ>? Ml7aNVQh\A>? MXvEUXNQ NFXQNXFFd2W|IH7veEBi\m[nY4SgR3hEWjRiZHXud4l1gQ>? NF35fVkyPzR6NUWwNS=>
HEK293 cells NIqy[pRMcW6jc3WgRZN{[Xl? NIW4Snc2OCCwTR?= NFLZb|M1PSCvaX6= M{X1dmROW09? NUfNSmpXUW6qaXLpeJMhdVSRUjDrbY5ie2ViYXP0bZZqfHlid3n0bEBKSzVyIH;mJFAvOSCwTR?= M1frZVE4OzVyOUWz
Drosophila melanogaster S2 cells transfected with N-luc and C-luc NELlcWJHfW6ldHnvckBCe3OjeR?= M3rDXlExOCCwTR?= NXrVOZZtPCCq M{W5eGROW09? NXnoNHN{UW6mdXPld{BtfWOrZnXyZZNmKHC{b4TlbY4hfHKjboOtd5BtcWOrbnegbY4hTHKxc3;wbIlt[SCvZXzhco9o[XO2ZYKgV|Ih[2WubIOgeJJidnOoZXP0[YQhf2m2aDDOMYx2[yCjbnSgR{1tfWN? NYj6PXZTOTdzMkiyOlI>
Human mixed lymphocyte MmPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXO3OZpVPSCwTR?= MUTEUXNQ M1jpXmlEPTB;MT62JI5ONg>? MYCxOlE5PTh4NR?=
Lewis rat lymph node cells MmrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIL3U|k2KM7:TR?= NYjhZ|dHTE2VTx?= NHOx[VJKSzVyPUKuOkDPxE1? MXWxOlE5PTh4NR?=
cells from the thymus of normal BALB/c mice M3XRNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXy3cHpqOTBibl2= M1XYUVczKGh? NVjlN4xzTE2VTx?= M2TVOmlvcGmkaYTzJIx6dXCqb4Dyc4xq\mW{YYTpc44hMEyDRjmge4l1cCCLQ{WwJI9nKDNibl2= M1Kxc|ExODJzOUS4
MRK-nu-1 MlfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;iUWlEPTB;MD64OFUheE1? M3PvbXNCVkeHUh?=
OCUB-M MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTVwMkSgdG0> MVHTRW5ITVJ?
SF539 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTFzLk[gdG0> M4rVRnNCVkeHUh?=
ES4 NX25XHRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFu3d|BKSzVyPUKxMlUheE1? MXXTRW5ITVJ?
RL95-2 M{XWfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTFyNzDwUS=> M3q3SnNCVkeHUh?=
LC-2-ad Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fyXmlEPTB;NEKzJJBO M1vubHNCVkeHUh?=
Daudi NUXQTWEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;UXGlEPTB;NEO0JJBO NIW5XVVUSU6JRWK=
NTERA-S-cl-D1 M3ezNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTR2MzDwUS=> M1L5N3NCVkeHUh?=
OS-RC-2 M1\oVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTZ3MjDwUS=> NIWxZoNUSU6JRWK=
VA-ES-BJ NX7jboZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrZT2Z{UUN3ME23NlMheE1? NHL3dG9USU6JRWK=
GR-ST NWPxclNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2j4XWlEPTB;OES2JJBO M{HT[3NCVkeHUh?=
SW872 NE\5R3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX30OYRWUUN3ME24OFYheE1? MVHTRW5ITVJ?
NOS-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI[wW41KSzVyPUi3NUBxVQ>? MUXTRW5ITVJ?
MC116 M2jxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3WxbWlEPTB;OUi1JJBO M3zSUXNCVkeHUh?=
NCI-H1355 NUm5RXI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTFwMEGgcm0> Ml3FV2FPT0WU
RPMI-8226 NF\PUGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTFwMUmgcm0> NF;sR3pUSU6JRWK=
TE-15 MmXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTSTWM2OD1zLkO2JI5O NXvQPWVRW0GQR1XS
Ramos-2G6-4C10 NILqVYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4[1cWlEPTB;MT60OkBvVQ>? NYDyVVgxW0GQR1XS
KU812 NXf5WnF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXiUFd2UUN3ME2yMlAyKG6P NGPvZ|RUSU6JRWK=
EW-1 NUXmU5B5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTJwMUegcm0> M4fPfXNCVkeHUh?=
KS-1 NIm0[4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPIe2RKSzVyPUKuOFUhdk1? MX\TRW5ITVJ?
SK-LMS-1 NVHlc|JLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTJwNEmgcm0> M1nSfnNCVkeHUh?=
TGBC1TKB MmTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{f1fWlEPTB;Mj62PUBvVQ>? MVHTRW5ITVJ?
TE-6 NI\rd2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TofWlEPTB;Mj63O{BvVQ>? MVrTRW5ITVJ?
ETK-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETmUohKSzVyPUKuPFIhdk1? NHi2S3RUSU6JRWK=
BE-13 NHjZcJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXCOGtXUUN3ME2yMlk6KG6P NHfxUWVUSU6JRWK=
A3-KAW MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\1fWlEPTB;Mj65PUBvVQ>? MXzTRW5ITVJ?
TE-10 NXvwN4ZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfjUoNKSzVyPUOuN{BvVQ>? MWTTRW5ITVJ?
DOHH-2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTNwM{Wgcm0> NYq4c4kzW0GQR1XS
ES6 Mn7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnNXpBtUUN3ME2zMlQ{KG6P MY\TRW5ITVJ?
OPM-2 NVvjOHhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnsd2g6UUN3ME20MlE2KG6P Mny4V2FPT0WU
SH-4 NFf4U3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFi3emJKSzVyPUSuN|Qhdk1? NY\TXFZtW0GQR1XS
NB13 MmHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjrdWFKSzVyPUSuN|Yhdk1? MnnmV2FPT0WU
HUTU-80 NHzHfFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7OTWM2OD12LkSyJI5O MmLVV2FPT0WU
CCRF-CEM NFzhSXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXnfFZHUUN3ME20Mlk1KG6P NH\KTIlUSU6JRWK=
TGBC24TKB M333V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\aTWM2OD13LkWxJI5O M{DQZXNCVkeHUh?=
697 M{nFTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfsR4E6UUN3ME22MlI5KG6P NID4XmRUSU6JRWK=
J-RT3-T3-5 MmLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkGyTWM2OD14LkS2JI5O MVjTRW5ITVJ?
KALS-1 M1\x[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTZwNU[gcm0> NYrnbJBZW0GQR1XS
no-10 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLXTWM2OD15LkK5JI5O NV\1OnRkW0GQR1XS
SK-NEP-1 NVXqTI1lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlSyTWM2OD16Lke5JI5O NUDJcI9rW0GQR1XS
L-540 Ml\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHyTWM2OD1zMD60NkBvVQ>? M{e3SHNCVkeHUh?=
JiyoyeP-2003 NEXIUJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfDW3JKSzVyPUGwMlk1KG6P NV;ucnFyW0GQR1XS
HH M4S1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDxT41LUUN3ME2xNU4{QSCwTR?= NELrT|ZUSU6JRWK=
SR MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTFzLkS1JI5O MlXJV2FPT0WU
QIMR-WIL M1vudmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPrcZR2UUN3ME2xNU45PSCwTR?= MnjLV2FPT0WU
A4-Fuk M2\hXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnlTWM2OD1zMz6xNkBvVQ>? NGTzcJVUSU6JRWK=
CESS MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHZTWM2OD1zMz6xN{BvVQ>? NHH6bVZUSU6JRWK=
KE-37 NFz4UphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGP4N|ZKSzVyPUG2MlA4KG6P M1zB[HNCVkeHUh?=
SK-UT-1 M17XXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\sRWlEPTB;MU[uPFEhdk1? MkPsV2FPT0WU
SIG-M5 Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1H0b2lEPTB;MUeuNlUhdk1? NUPiZmtHW0GQR1XS
HT MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HPemlEPTB;MUeuOkBvVQ>? M1eyeHNCVkeHUh?=
DEL MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXF[Ik6UUN3ME2xO{46QSCwTR?= MnniV2FPT0WU
SK-PN-DW NH;4[lRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLWXFF{UUN3ME2yNE4zOyCwTR?= NYXRbWZVW0GQR1XS
RPMI-8402 Mk\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTJzLke3JI5O NFmyUplUSU6JRWK=
RPMI-6666 MmL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TDZmlEPTB;MkSuOFIhdk1? NVHxPGFGW0GQR1XS
NCI-H720 NIjXboJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\6[ZpKSzVyPUK1MlQyKG6P MWfTRW5ITVJ?
EW-16 NVrLU45pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjqUZFKSzVyPUK2Mlg4KG6P MULTRW5ITVJ?
BL-70 MkH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPjXXRKSzVyPUK4MlM5KG6P NETZd4VUSU6JRWK=
SF126 M1HVd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTrTWM2OD1|MD6zPEBvVQ>? MXzTRW5ITVJ?
BC-1 M2LPUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7VVmhjUUN3ME2zNU4zPiCwTR?= NVLMcVZtW0GQR1XS
MHH-PREB-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NID0U21KSzVyPUOyMlQ1KG6P Mn\hV2FPT0WU
A101D M4DXSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfFVow1UUN3ME2zNk43OiCwTR?= M{f5WnNCVkeHUh?=
NMC-G1 NFW0e2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3WTWM2OD1|Mz62O{BvVQ>? MkDzV2FPT0WU
LB1047-RCC NWf5VVVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTN2Lk[5JI5O NVfvXGlWW0GQR1XS
EM-2 MknNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vq[mlEPTB;M{iuOVMhdk1? NFT2W|hUSU6JRWK=
COLO-684 NIO2W45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\wcmNKSzVyPUO5Mlghdk1? Mn7iV2FPT0WU
Becker M1HNWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\KTWM2OD12MT6wOUBvVQ>? NEnXcWpUSU6JRWK=
BL-41 M2ruZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTKUo9KSzVyPUSzMlY3KG6P MmizV2FPT0WU
MDA-MB-134-VI M2K0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3jTWM2OD12ND6wNkBvVQ>? M2nURnNCVkeHUh?=
L-363 M{PacGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrKUXZKSzVyPUS0Mlc{KG6P NWnkWYZuW0GQR1XS
ECC4 MnHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTR2Lke4JI5O M2q5N3NCVkeHUh?=
A388 M3;nPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVSyPZdHUUN3ME20OE45OiCwTR?= M3TKbHNCVkeHUh?=
HEL NUTtNYU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnMem9WUUN3ME20PU44QSCwTR?= MULTRW5ITVJ?
RKO MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnP0TWM2OD13MD6yPUBvVQ>? NUHQSVJvW0GQR1XS
KINGS-1 NUe2dI42T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LVbmlEPTB;NUGuOVUhdk1? MoD6V2FPT0WU
EB-3 NYPxcIxLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrCTWM2OD13Mj62O{BvVQ>? MnrvV2FPT0WU
ARH-77 M2H6bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorWTWM2OD13Mj64JI5O M4rKPHNCVkeHUh?=
GCIY MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTV|LkS2JI5O MoHIV2FPT0WU
NCI-H1304 NXPxeo0{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrXXVBKSzVyPUW3MlIzKG6P MVrTRW5ITVJ?
KARPAS-299 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTZzLkiyJI5O NFzhR2xUSU6JRWK=
IA-LM M4jZWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXGbVhJUUN3ME22PE4yOyCwTR?= MnnDV2FPT0WU
GI-1 MljJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLMTWM2OD15MD6zPUBvVQ>? M1rVNHNCVkeHUh?=
TE-11 NGnFSmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTd5LkG3JI5O NEDnWppUSU6JRWK=
LS-411N MlXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXixd3JNUUN3ME23O{42PyCwTR?= MkPrV2FPT0WU
no-11 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vZTGlEPTB;OEOuNlQhdk1? NUfLNWRbW0GQR1XS
MV-4-11 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHQ[HlpUUN3ME24N{44OyCwTR?= NEXNUlJUSU6JRWK=
BV-173 M{DJWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\XW2lEPTB;OEOuPVchdk1? M3LENnNCVkeHUh?=
CMK NWjPPYh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfZTWM2OD16ND6xOkBvVQ>? MWXTRW5ITVJ?
LC4-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTh4LkeyJI5O M4rCUHNCVkeHUh?=
COR-L279 NYfVeFNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTh5LkK1JI5O MWfTRW5ITVJ?
NCI-H209 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7DSXVSUUN3ME24O{41OSCwTR?= NHvIeplUSU6JRWK=
Raji MkHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFy5[GVKSzVyPUi5MlczKG6P NH:xZYhUSU6JRWK=
LB996-RCC NXLKe5dLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnYV4Y5UUN3ME25N{41OyCwTR?= NHPIV2JUSU6JRWK=
NCI-H526 M2S1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTl|LkW5JI5O MlzwV2FPT0WU
KGN M1jLVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXVe5J5UUN3ME25Ok4zQSCwTR?= NFPRWmlUSU6JRWK=
MOLT-4 MnTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjyS3BVUUN3ME25Ok44QSCwTR?= NVXaV2hpW0GQR1XS
PF-382 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTl4Lke5JI5O MoXNV2FPT0WU
BC-3 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTl7LkG4JI5O MVnTRW5ITVJ?
KARPAS-422 NHjIcJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTFyMj6wPUBvVQ>? NFu3NGxUSU6JRWK=
SBC-1 M13FfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jXe2lEPTB;MUC3Mlc2KG6P NXezc3JyW0GQR1XS
LC-1F NWLlU4pvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPETWM2OD1zMEiuNFUhdk1? NHHTbXhUSU6JRWK=
GB-1 MmDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4L2bWlEPTB;MUC5MlAzKG6P M3LB[nNCVkeHUh?=
SNB75 M37M[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTFzOT62PUBvVQ>? M321XHNCVkeHUh?=
BB65-RCC MonZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4SweWlEPTB;MUG5Mlk{KG6P NYXv[WVrW0GQR1XS
NCI-N87 NUK3TlY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTF{MT65PEBvVQ>? MoW2V2FPT0WU
IST-MEL1 NXvMboVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3RbmlKSzVyPUGyNk4{QCCwTR?= NUjmTFVRW0GQR1XS
HOP-62 NWm2UZpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTF{Nj64PUBvVQ>? MX7TRW5ITVJ?
ACN NF7D[m5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TpT2lEPTB;MUS2Mlc2KG6P MnHrV2FPT0WU
DMS-114 NUDsVY9LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTF3MD62O{BvVQ>? MWfTRW5ITVJ?
MLMA NUHsZ4dXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmq5TWM2OD1zNUmuPFghdk1? NYjpeopCW0GQR1XS
HT-144 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTF4NT60N{BvVQ>? Ml;IV2FPT0WU
C2BBe1 M{TtR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWi3Z4E5UUN3ME2xOlcvPzZibl2= NEXwV4NUSU6JRWK=
L-428 MoXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPlW5NKSzVyPUG3O{44KG6P MoLpV2FPT0WU
DU-4475 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWKwOnI6UUN3ME2xPFcvPjhibl2= M3jHTHNCVkeHUh?=
CP67-MEL NVj6TVIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3myO2lEPTB;MUm5MlM5KG6P NIPIO2pUSU6JRWK=
MEG-01 MlfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXJTpBOUUN3ME2yNFEvQTZibl2= M{fhb3NCVkeHUh?=
IST-SL2 M2Dtc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTJyOD62N{BvVQ>? M3XhNnNCVkeHUh?=
ES8 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTJ{NT65OEBvVQ>? NWfhRVJOW0GQR1XS
COLO-800 NXexbpBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnr3TWM2OD1{M{WuNlghdk1? MlLRV2FPT0WU
MFH-ino NYXNOHh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDlNXBIUUN3ME2yN|UvQDRibl2= NVjxc4hLW0GQR1XS
OVCAR-4 NHH6O2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XrbWlEPTB;MkO3MlI1KG6P MUnTRW5ITVJ?
PSN1 M3nSTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M36x[2lEPTB;MkSyMlcyKG6P M1zpXnNCVkeHUh?=
EW-12 NFPOVVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTJ2Mz6xJI5O M1fXSHNCVkeHUh?=
HCC1599 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTXcZhTUUN3ME2yOlEvPDdibl2= Mkj1V2FPT0WU
SJSA-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTJ5MT60OkBvVQ>? M{HjSXNCVkeHUh?=
ST486 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\1R2VKSzVyPUK5Ok4yPCCwTR?= Mm\FV2FPT0WU
NOMO-1 NVS5ToE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLwTWM2OD1|MECuNlEhdk1? NGn1OWdUSU6JRWK=
MN-60 MmH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTNyNT6zNkBvVQ>? MnOwV2FPT0WU
HCC1187 NWDPNnJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrpWXVKSzVyPUOwO{4zPSCwTR?= NFSy[FlUSU6JRWK=
SW982 NUHQcmZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{m2[mlEPTB;M{G0Mlc2KG6P NVvnbJJtW0GQR1XS
LB647-SCLC M3HReWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLZWZdMUUN3ME2zNlgvPzFibl2= NXjCZ5QxW0GQR1XS
HC-1 MoH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfYc5VKSzVyPUOzOU42KG6P M1XIO3NCVkeHUh?=
EHEB M{TqRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlf2TWM2OD1|M{euOVIhdk1? NITrWVdUSU6JRWK=
TUR M2fUb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTrTWM2OD1|NkOuPVUhdk1? MXrTRW5ITVJ?
LU-139 NIG5b2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzEN40zUUN3ME2zO|gvODJibl2= MVnTRW5ITVJ?
NB1 NYXpTIpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfqb2VOUUN3ME2zPFQvPDVibl2= NYnoVGlZW0GQR1XS
BB30-HNC MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTN6OD6zNkBvVQ>? M3;MR3NCVkeHUh?=
HAL-01 MnHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLwPGtDUUN3ME2zPFkvOjZibl2= NY\IT2pPW0GQR1XS
K5 NFvEVm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXqTWM2OD12MUGuN|chdk1? NH;ROpZUSU6JRWK=
MZ2-MEL M4fvSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTtT2ZKSzVyPUSxN{43PCCwTR?= MX;TRW5ITVJ?
RXF393 M{LOUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLKdIpqUUN3ME20NVYvPDVibl2= MkKyV2FPT0WU
NCI-H1648 NYSzPFFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{[3NGlEPTB;NEG3MlU{KG6P M1n6e3NCVkeHUh?=
TE-12 M{LqdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLrTG9KSzVyPUSzOE4zPiCwTR?= M3PLUXNCVkeHUh?=
EoL-1- NUjHb2RuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjacYdKSzVyPUSzO{46QCCwTR?= MV7TRW5ITVJ?
JAR MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWH2W4NtUUN3ME20N|gvPjJibl2= Mm\mV2FPT0WU
DSH1 MkjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn75TWM2OD12NUiuPVEhdk1? M1X5cnNCVkeHUh?=
NCI-H187 M4D3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTR4Mj64NUBvVQ>? NXPGdJpvW0GQR1XS
HCE-4 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHNTWM2OD12N{euOlYhdk1? M3ro[3NCVkeHUh?=
8-MG-BA NXTnTY5iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rWNWlEPTB;NUixMlUzKG6P NYXOVldHW0GQR1XS
KLE M2\V[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTV6NT6yJI5O NY\uXJY5W0GQR1XS
KNS-42 NYnnUFk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV:5OXM4UUN3ME21PFYvQDFibl2= NWXSTo5[W0GQR1XS
MSTO-211H Mn\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nOfWlEPTB;NkC5Mlc1KG6P Mn;iV2FPT0WU
GDM-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvUbI5KSzVyPU[xOE4xQSCwTR?= NFHUNVhUSU6JRWK=
TE-1 MmLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTZ2Nj6xNkBvVQ>? M3nDTHNCVkeHUh?=
BT-474 MlnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTZ2Nz6wOkBvVQ>? MVvTRW5ITVJ?
KARPAS-45 MkfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEK2eYJKSzVyPU[0O{43KG6P MoTyV2FPT0WU
MOLT-16 NVWxdWM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLwTWM2OD14NEeuPVMhdk1? M2jySHNCVkeHUh?=
KURAMOCHI M4\RWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrUTWM2OD14NUeuOVEhdk1? NIfUNnJUSU6JRWK=
K-562 MoPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFj0fWlKSzVyPU[2PU42OSCwTR?= NH;Rd29USU6JRWK=
EKVX NX7zXFRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fQVWlEPTB;NkeyMlcyKG6P MY\TRW5ITVJ?
GAK NY\wfWdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HRfWlEPTB;Nke1MlMhdk1? NHjTe3ZUSU6JRWK=
NCI-SNU-5 NX[5eFMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDTbpF{UUN3ME22PVAvODFibl2= MVXTRW5ITVJ?
NCI-H2126 Mo\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvKTWM2OD15Mk[uPFchdk1? NWrWNnNxW0GQR1XS
CTV-1 M2HUTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTd2ND65JI5O MkPFV2FPT0WU
SW962 NEXpXJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTd2OD60OEBvVQ>? NYruW4xFW0GQR1XS
MONO-MAC-6 NVziOIJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjpTnlKSzVyPUe1Ok46OyCwTR?= NYT3clM1W0GQR1XS
NCI-H748 Mo[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\xTWM2OD15NUiuPVkhdk1? NX;hNVV4W0GQR1XS
NCI-H524 MnTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFr1ZWhKSzVyPUe4NE44OyCwTR?= M3rXWXNCVkeHUh?=
LS-123 NIS1SGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LDcWlEPTB;N{m1MlY6KG6P NF;2RWhUSU6JRWK=
NB7 NY\JO3RyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzkcJVFUUN3ME24NVQvOTRibl2= M1zWXnNCVkeHUh?=
LS-1034 NGHocm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17lWGlEPTB;OEK4Mlk5KG6P NEG0ZpVUSU6JRWK=
TE-5 MlnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4i1SGlEPTB;OEizMlU3KG6P NF3KOHBUSU6JRWK=
A704 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;HTJFKSzVyPUi5PU4yPSCwTR?= NEPQToNUSU6JRWK=
TK10 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTlzNj6wN{BvVQ>? MnfNV2FPT0WU
NCI-H345 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFOwbppKSzVyPUm0N{4zOiCwTR?= NETje4pUSU6JRWK=
CGTH-W-1 NIjXfFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mni5TWM2OD17NEiuNVMhdk1? MXLTRW5ITVJ?
NCI-H510A NGP2V|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHmTWM2OD17OEWuNVIhdk1? M{Dle3NCVkeHUh?=
NCI-H1963 NHzVbXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDI[5FIUUN3ME2xMlA{Ojl{IN88US=> NFPaU2pUSU6JRWK=
SCC-3 NF;NVpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrnUZB4UUN3ME2xMlA{PDF2IN88US=> M3KzWnNCVkeHUh?=
EW-11 NHnDOmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{T3PWlEPTB;MT6wPFc1OyEQvF2= NXXFT3B3W0GQR1XS
CPC-N MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PoNmlEPTB;MT6wPFgh|ryP MoHQV2FPT0WU
NCI-H1417 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPHUlV4UUN3ME2xMlEzOjZizszN MVTTRW5ITVJ?
DG-75 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTidINKSzVyPUGuNVYzQDVizszN M36zZXNCVkeHUh?=
HD-MY-Z MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLZTWM2OD1zLkG2OFE3KM7:TR?= NWPTe|ZsW0GQR1XS
ATN-1 NWHI[3lVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoC2TWM2OD1zLkK2NlA6KM7:TR?= NHjUTI9USU6JRWK=
KM-H2 NWjQW5d2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrjO3RKSzVyPUGuNlY1ODhizszN NYPjWHIxW0GQR1XS
NCI-H2081 NXz3bIN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37LTGlEPTB;MT6yOlY{PyEQvF2= NV;3VHhlW0GQR1XS
HL-60 M1;yeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTFwMk[5OVkh|ryP NEjF[nVUSU6JRWK=
DB M3Hhd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmO2TWM2OD1zLkK3NlQzKM7:TR?= NYXiUY52W0GQR1XS
NCI-H1522 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTFwMki4PFch|ryP NWS0T4dqW0GQR1XS
AM-38 Mmi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DC[mlEPTB;MT6zNFczKM7:TR?= NHzqZ2JUSU6JRWK=
NCI-H446 NYm1OGFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTFwM{KxNlEh|ryP M2DBdXNCVkeHUh?=
SU-DHL-1 MoDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTFwM{K4NFEh|ryP NX6zXYp2W0GQR1XS
NH-12 NGHLS2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTFwM{[zO|Qh|ryP NEfkRnRUSU6JRWK=
DMS-79 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTFwM{[4OlYh|ryP NW\Yd5hsW0GQR1XS
NCI-H716 M4rWPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3niRWlEPTB;MT6zPFk5PiEQvF2= NVW2TFF6W0GQR1XS
ML-2 NESx[IpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnKWY1KSzVyPUGuOFE2OjlizszN Mmq2V2FPT0WU
NB10 NX7P[4hmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPqTWM2OD1zLkS2OlMzKM7:TR?= MXzTRW5ITVJ?
ONS-76 M2ftemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jE[mlEPTB;MT61N|U3QSEQvF2= M1vXZnNCVkeHUh?=
LOUCY M2rFVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYW0S3ZoUUN3ME2xMlU1PjV5IN88US=> MmnmV2FPT0WU
SCLC-21H MnfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlziTWM2OD1zLkW4OVgzKM7:TR?= MY\TRW5ITVJ?
TGW M{TRS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHX5cpNKSzVyPUGuOlM6PzVizszN NXLs[4xpW0GQR1XS
LXF-289 NHHzVlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkO4TWM2OD1zLkezNlY5KM7:TR?= MYfTRW5ITVJ?
BB49-HNC NFTUNHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTFwN{O1PFYh|ryP M37iSXNCVkeHUh?=
NCI-H747 MnjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH76dZZKSzVyPUGuO|U{PDZizszN MYXTRW5ITVJ?
LU-165 NXHaXXJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\qTWM2OD1zLki0PVg3KM7:TR?= NFLR[5FUSU6JRWK=
OMC-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYn6fXd3UUN3ME2xMlk2ODZ4IN88US=> NYLON2RFW0GQR1XS
RCC10RGB NELGVGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nOcGlEPTB;MT65OVgyPyEQvF2= NXHDTpdHW0GQR1XS
SW684 NXnJRVNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTFwOU[wPVkh|ryP NGXUXo9USU6JRWK=
TE-8 M4TaR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\sTFJZUUN3ME2yMlA2PTV7IN88US=> MWHTRW5ITVJ?
SK-N-DZ NYnVN5FUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDQbWdUUUN3ME2yMlE{Ojd2IN88US=> NF7sOY5USU6JRWK=
EVSA-T MmT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIP0RlJKSzVyPUKuNVc{OTVizszN NI\jVYdUSU6JRWK=
KASUMI-1 M4fVO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnxWm5YUUN3ME2yMlE5QDF3IN88US=> Mk[0V2FPT0WU
NKM-1 MkHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUP4VHh2UUN3ME2yMlI2PDd{IN88US=> NGrtNFRUSU6JRWK=
CAL-148 Mlf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXz5cJZ3UUN3ME2yMlM{PjF2IN88US=> MWTTRW5ITVJ?
NCI-H64 Moe3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVywRpR1UUN3ME2yMlM1OjN{IN88US=> MnXVV2FPT0WU
KNS-81-FD NIDFZVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvNTWM2OD1{LkO2OlIh|ryP M4D5ZXNCVkeHUh?=
KM12 M{TUbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmezTWM2OD1{LkSwPFM6KM7:TR?= MWLTRW5ITVJ?
SW954 NVjlR|J7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTJwNEe3O|kh|ryP MmLqV2FPT0WU
NCI-H1395 Mnv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTJwNUK2OFUh|ryP MlnxV2FPT0WU
DJM-1 NX7q[pZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXsTWM2OD1{Lk[wOlMh|ryP MmTtV2FPT0WU
COLO-668 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\ETWM2OD1{LkiyOlk2KM7:TR?= MW\TRW5ITVJ?
NCI-H1436 NHPObGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfaV2ZpUUN3ME2yMlg2PjF3IN88US=> M{ThRXNCVkeHUh?=
LB2241-RCC MoT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33J[2lEPTB;Mj64Olg{QSEQvF2= NGm2NFZUSU6JRWK=
GT3TKB MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTJwOEmwOVUh|ryP NWTBOYFYW0GQR1XS
COLO-824 NY\p[HBuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYm0R4hnUUN3ME2yMlg6PzZ6IN88US=> M4rwN3NCVkeHUh?=
ES1 M4TBfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{O5fWlEPTB;Mj64PVg4QSEQvF2= M1Lne3NCVkeHUh?=
LB771-HNC NVrzc|VlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTJwOUC5OFYh|ryP MUnTRW5ITVJ?
GI-ME-N NX:5[XY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTNwMEC5NFQh|ryP M4KzRXNCVkeHUh?=
NALM-6 M3zhemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\DU5VKSzVyPUOuNFA6OzNizszN NIWxWGtUSU6JRWK=
LU-134-A M3HvOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXIS5lKSzVyPUOuNFU1OjVizszN NF3HSFRUSU6JRWK=
DMS-153 M4PGeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoixTWM2OD1|LkC1PFI1KM7:TR?= MX7TRW5ITVJ?
MZ1-PC MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LBR2lEPTB;Mz6wPVA4QCEQvF2= M{\CdHNCVkeHUh?=
NCI-H1155 NUP4VIV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTKd2hPUUN3ME2zMlEyPjFizszN MUHTRW5ITVJ?
CAS-1 NVKycno2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzlfnVKSzVyPUOuNVM4ODdizszN M2HRS3NCVkeHUh?=
D-502MG NHTSRohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mln0TWM2OD1|LkG0N|kh|ryP M4fVNnNCVkeHUh?=
NCI-H2141 NHzCdWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvEd2RyUUN3ME2zMlE4PDV{IN88US=> NGXPWGtUSU6JRWK=
NB6 NXHZSYxOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XZSWlEPTB;Mz6xPFI2QSEQvF2= NH;UNFVUSU6JRWK=
NCCIT MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfuVXJKSzVyPUOuNlE5ODlizszN NUX1elJ4W0GQR1XS
NB69 M4\ZXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XZ[WlEPTB;Mz6zNVg6OSEQvF2= MVfTRW5ITVJ?
JVM-2 Mn7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnxbIl2UUN3ME2zMlM3PDN|IN88US=> MVHTRW5ITVJ?
K052 NVztNIF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\2UmtKSzVyPUOuN|c6PjhizszN M3;6UHNCVkeHUh?=
HCC2157 M{jTVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFSyVJBKSzVyPUOuOVMzOjhizszN NH;OcFVUSU6JRWK=
KMOE-2 NUnaT|h{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTNwNUSyOFIh|ryP M{PWbnNCVkeHUh?=
SF268 MkK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTNwN{G1OVQh|ryP M4\u[3NCVkeHUh?=
CHP-126 NFzIcGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{OzN2lEPTB;Mz63OlQ2QCEQvF2= M{PqXXNCVkeHUh?=
CP66-MEL NUDnVJV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTNwN{mwPVQh|ryP MmP1V2FPT0WU
NCI-H69 M17hbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4T1c2lEPTB;ND6wNVk{PiEQvF2= M13qTnNCVkeHUh?=
A253 NGC0e4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEH2ZWhKSzVyPUSuNFIyODFizszN M3nWfXNCVkeHUh?=
NB14 NHXRe|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTRwMUC0O|kh|ryP NGLYNldUSU6JRWK=
NCI-H1694 NF30OFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHH[FdKSzVyPUSuNVMyOTJizszN MUTTRW5ITVJ?
NCI-H2196 NX\2TJdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknsTWM2OD12LkG3NVY6KM7:TR?= NE\ONFVUSU6JRWK=
TE-9 NUfwdVlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmS1TWM2OD12LkG3OVgzKM7:TR?= M1zlV3NCVkeHUh?=
D-283MED MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmL6TWM2OD12LkG4PFQh|ryP Mln4V2FPT0WU
OCI-AML2 M1fBVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTRwMUm0PFkh|ryP MmLmV2FPT0WU
D-263MG M3r4cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTRwMkK5OlEh|ryP NXfIeGZ[W0GQR1XS
MPP-89 NVHGN|QzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DnVmlEPTB;ND6yO|MxPCEQvF2= MWnTRW5ITVJ?
LAMA-84 NGHhN|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjOTWM2OD12LkOwOFIyKM7:TR?= MXvTRW5ITVJ?
LB373-MEL-D M3L1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnruTWM2OD12LkO2O|g6KM7:TR?= M2jjSXNCVkeHUh?=
UACC-257 NHfFe2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTRwM{m1N|Qh|ryP NW[2VmNEW0GQR1XS
MC-CAR MknQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrvZVRKSzVyPUSuOFM6QSEQvF2= NVLxcoJMW0GQR1XS
COLO-320-HSR NEfUVYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfXTWM2OD12LkS0OFI4KM7:TR?= MY\TRW5ITVJ?
P30-OHK MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTRwNk[1PFEh|ryP M3f4fXNCVkeHUh?=
UACC-812 NVfNWllET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonMTWM2OD12Lk[5NVYyKM7:TR?= MlXBV2FPT0WU
CTB-1 MkX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHviSJZKSzVyPUSuO|E2PTVizszN NGXHU5NUSU6JRWK=
ALL-PO NGntelJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTRwOESwO|ch|ryP M3POTnNCVkeHUh?=
SK-MEL-2 NWn3SVhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3Rb4FIUUN3ME20Mlg3QTV3IN88US=> NHHBd|hUSU6JRWK=
TC-YIK Mn;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHKb45KSzVyPUSuPVc6PDJizszN NFS3ZmlUSU6JRWK=
NCI-H1882 MnfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTVwMEKwNFEh|ryP NF;Zc|hUSU6JRWK=
MHH-CALL-2 M4fMdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zJRWlEPTB;NT6wOVA1OiEQvF2= MYrTRW5ITVJ?
U-87-MG NFG3eWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTyVmxKSzVyPUWuNFk1PjZizszN MYnTRW5ITVJ?
NCI-H1092 NGe3WnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTYR2pYUUN3ME21MlI3PTV3IN88US=> NGLNdlVUSU6JRWK=
TE-441-T MljSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTVwMke4NkDPxE1? M{XZ[XNCVkeHUh?=
SK-MEL-1 MlS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFn6N5RKSzVyPUWuNlkxPDRizszN M4TucnNCVkeHUh?=
EW-22 M{Drc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml70TWM2OD13LkK5OFY3KM7:TR?= Ml3CV2FPT0WU
MZ7-mel MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfsTWM2OD13LkSwOlkyKM7:TR?= Mn7wV2FPT0WU
LP-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXINJk{UUN3ME21MlQyOjlzIN88US=> M1;lSXNCVkeHUh?=
NCI-SNU-16 NEHUZolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTVwNkSwO|Qh|ryP NE\mUZhUSU6JRWK=
LU-65 M1vZdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfHZWJKSzVyPUWuO|Y{PzNizszN NEHOUINUSU6JRWK=
CW-2 NET2dZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVv3fJlnUUN3ME21Mlg2QTV7IN88US=> Ml3mV2FPT0WU
WSU-NHL NIj5SIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33GfWlEPTB;NT65OVE4PCEQvF2= MmjsV2FPT0WU
IST-MES1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTVwOUW0OFMh|ryP M{L3R3NCVkeHUh?=
U-266 NHfn[HBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVe5U49IUUN3ME21Mlk5OjB{IN88US=> Ml3wV2FPT0WU
TALL-1 M12wVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTZwMUS2PFgh|ryP NULreot{W0GQR1XS
Calu-6 MnPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fvRmlEPTB;Nj6xOVMyPiEQvF2= NUTtbmRUW0GQR1XS
MMAC-SF M2C1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PiWWlEPTB;Nj6xPFU2PiEQvF2= NYjU[mJFW0GQR1XS
NCI-H82 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4ryTWlEPTB;Nj6yNFQ5QSEQvF2= MlzCV2FPT0WU
RS4-11 MmfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoKzTWM2OD14LkK1PFk4KM7:TR?= NIq1cJlUSU6JRWK=
SNU-C2B NV[wVIhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWqxWFM5UUN3ME22MlQxQTZ7IN88US=> NFj6cIJUSU6JRWK=
BOKU MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGj0b2lKSzVyPU[uOFc2QTdizszN NGXafZZUSU6JRWK=
C8166 NV7LcphzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITaUoNKSzVyPU[uOVU6OTJizszN MV;TRW5ITVJ?
D-247MG NYTvdI5YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2G3OmlEPTB;Nz6wOFM1PyEQvF2= MUnTRW5ITVJ?
EW-18 M375cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELTWHlKSzVyPUeuNFczQTJizszN MVfTRW5ITVJ?
KG-1 MonsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPlTWM2OD15Lk[yO|M5KM7:TR?= NXHUUmNvW0GQR1XS
REH NWfZSIRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3e5NmlEPTB;Nz62PFExQSEQvF2= NEXrb5lUSU6JRWK=
U-698-M MknDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnRUmRKSzVyPUeuPFQ{OTVizszN NUW1enBCW0GQR1XS
KP-N-RT-BM-1 NHrTXmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HLZ2lEPTB;Nz65N|AzQSEQvF2= NHnkSIFUSU6JRWK=
MS-1 NIjoTYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rr[2lEPTB;Nz65OlA1OSEQvF2= NGGxemhUSU6JRWK=
SNU-C1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjNTWM2OD15Lkm4NVkzKM7:TR?= NIPFb5ZUSU6JRWK=
SK-MM-2 NWTtTXNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRThwMk[wOlUh|ryP MkPzV2FPT0WU
LAN-6 NEfmSnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHDTWM2OD16LkOwNFAyKM7:TR?= NWHib4h7W0GQR1XS
NEC8 MlLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLtNXdKSzVyPUiuN|A3QTFizszN NELTfphUSU6JRWK=
NCI-H1770 NVKwOpY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3e0ZmlEPTB;OD6zPFAxOiEQvF2= NUK2SZRHW0GQR1XS
D-336MG NHe2N3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRThwNECxNVYh|ryP M{PydXNCVkeHUh?=
COLO-829 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRThwNEi4O|kh|ryP MXLTRW5ITVJ?
LS-513 NHKwd|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1yySWlEPTB;OD61PVU6QSEQvF2= NGXU[3ZUSU6JRWK=
YT MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLyTWM2OD16Lk[yOFI4KM7:TR?= NFq3XoFUSU6JRWK=
EW-24 MnrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\4Oo1KSzVyPUiuO|Y2PCEQvF2= M4naTXNCVkeHUh?=
IST-SL1 NIDhfXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DNO2lEPTB;OD64OlU1OyEQvF2= NYj2TYZzW0GQR1XS
CA46 NGPNOlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nDcGlEPTB;OD65OVA6QCEQvF2= NY[zVVF{W0GQR1XS
NCI-H1838 MoixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17IXmlEPTB;OD65PFYxOiEQvF2= NF7YXoRUSU6JRWK=
NCI-H719 NWDEe2RuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLZTWM2OD17LkK1Nlc6KM7:TR?= M4T5dXNCVkeHUh?=
HCE-T MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTlwM{C4OVEh|ryP M{PFXnNCVkeHUh?=
A498 M3PuPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TkXGlEPTB;OT6zOlEzPCEQvF2= MV\TRW5ITVJ?
LB831-BLC MnfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7JTWM2OD17Lke2OVIyKM7:TR?= NFPoOYdUSU6JRWK=
SKM-1 NIfLUlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXv6dFA2UUN3ME25Mlg2QTZ|IN88US=> MXTTRW5ITVJ?
THP-1 NGPhN25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDRTWM2OD17Lkm2PVE5KM7:TR?= MoXaV2FPT0WU
SHP-77 NVXKS2dvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWH4NJhGUUN3ME2xNE41ODdizszN MnL4V2FPT0WU
EW-3 NWXSPHNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DYR2lEPTB;MUCuOlI5QSEQvF2= NH;L[XdUSU6JRWK=
KY821 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTFyLke2N{DPxE1? MUPTRW5ITVJ?
NCI-SNU-1 MojLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;FTWM2OD1zMT6wNlE4KM7:TR?= MlnSV2FPT0WU
HCC2218 NE\sfINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rYT2lEPTB;MUGuN|k5PiEQvF2= MVzTRW5ITVJ?
IM-9 NWXQe4FvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTFzLkWxNFYh|ryP MVfTRW5ITVJ?
NCI-H889 M{njWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjQN5d3UUN3ME2xNU42OzF|IN88US=> M1XEcnNCVkeHUh?=
HDLM-2 NWTVSmcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHpV|VKSzVyPUGyMlQyPTlizszN M1fWdXNCVkeHUh?=
LB2518-MEL NHn3U4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnCTWM2OD1zMj62PFE2KM7:TR?= NEPnN4pUSU6JRWK=
NCI-H23 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{G4fGlEPTB;MUOuNlQzPSEQvF2= NFvabZVUSU6JRWK=
NB17 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTF|LkS1O|kh|ryP M4njcnNCVkeHUh?=
NCI-H322M MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH:3bJlKSzVyPUG0MlQxPjhizszN M3HLT3NCVkeHUh?=
SUP-T1 M{H0fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn2wTWM2OD1zND60NVMh|ryP MnzPV2FPT0WU
ES3 M{LQWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTPTWM2OD1zNT6wO|A{KM7:TR?= MmrMV2FPT0WU
ES5 NELvZW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPBTWM2OD1zNT6wO|g4KM7:TR?= M3[4cHNCVkeHUh?=
NCI-H1650 M1zYU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljtTWM2OD1zNT60PVc6KM7:TR?= NUOxeHNsW0GQR1XS
NCI-H226 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHu3R|dKSzVyPUG1Mlg4PjhizszN MXHTRW5ITVJ?
COR-L88 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTFVJF1UUN3ME2xOk4{OTRizszN Mli3V2FPT0WU
SCC-15 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnW[|VYUUN3ME2xOk4{QDZ7IN88US=> MYLTRW5ITVJ?
GOTO MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LofWlEPTB;MU[uOFc6OyEQvF2= MmfWV2FPT0WU
SIMA MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTF4LkS4NFIh|ryP NIXDRWFUSU6JRWK=
NCI-H1299 NGG2fmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTF5LkG1PVEh|ryP MnvpV2FPT0WU
NCI-H1581 NVjVSWxHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fCW2lEPTB;MUeuOFIyQSEQvF2= M{HyWXNCVkeHUh?=
MHH-NB-11 M2nh[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTF5Lkm2PFMh|ryP MUPTRW5ITVJ?
MFM-223 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4flbWlEPTB;MUiuNFU{QCEQvF2= MkHEV2FPT0WU
ES7 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XJPGlEPTB;MUiuOVQ{OSEQvF2= M4r0bHNCVkeHUh?=
JVM-3 NGfGSYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7RSJJKSzVyPUG4MlcyPyEQvF2= NV:0WGttW0GQR1XS
RL MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXMeop2UUN3ME2yNE4{QDhizszN MWjTRW5ITVJ?
EC-GI-10 NFTsb3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDKbW02UUN3ME2yNU4zODRzIN88US=> MYTTRW5ITVJ?
LNCaP-Clone-FGC MmO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTJzLk[3Olgh|ryP Mnf2V2FPT0WU
IMR-5 M{\2[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DhNGlEPTB;MkGuPFQ6PCEQvF2= NG\5V|ZUSU6JRWK=
KP-N-YS NVvrSoNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTJzLki3OUDPxE1? MoDmV2FPT0WU
Mo-T M1TaZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoqwTWM2OD1{Mj6yNVg2KM7:TR?= MXTTRW5ITVJ?
NCI-H128 MnywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTJ|LkW4OVMh|ryP M3\vfHNCVkeHUh?=
RH-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTJ|Lke4OlYh|ryP M3jHfHNCVkeHUh?=
NCI-H2171 M{PxNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPtTWM2OD1{ND6yOFg2KM7:TR?= MlPlV2FPT0WU
RPMI-8866 M{PvU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITkPIVKSzVyPUK2Mlc1OiEQvF2= NVPESpdvW0GQR1XS
SK-N-FI NWjOXldKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzOe3BKSzVyPUK3MlM5OTFizszN M3[2XHNCVkeHUh?=
LOXIMVI MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTJ5LkiwOVEh|ryP MoHOV2FPT0WU
P31-FUJ MoLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXqUWk1UUN3ME2zNU42Ozd2IN88US=> MnG1V2FPT0WU
KMS-12-PE NGPQN4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;QeIhKSzVyPUS5MlU{ODJizszN M{nue3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

体内研究 在体内,Rapamycin 处理,特定阻断mTOR下游靶点,如p70S6K磷酸化和激活,和PHAS-1/4E-BP1导致的eIF4E抑制释放, 完全阻断跖肌重量和纤维尺寸的肥厚增高。[3] 短期Rapamycin处理,即使按最低剂量0.16 mg/kg处理, 强抑制p70S6K活性, 与提高的肿瘤细胞死亡和Eker肾脏肿瘤坏死相关。[4] Rapamycin作用于CT-26移植瘤模型,通过降低VEGF产量,及阻断VEGF诱导的内皮细胞信号,而抑制转移性肿瘤生长和血管新生。[5] Rapamycin每天按4 mg/kg剂量处理C6移植瘤,显著降低肿瘤生长,和肿瘤血管通透性。[7]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

mTOR激酶免疫印迹法测定:

HEK293细胞按每孔2-2.5×105个细胞接种在12孔板上,DMEM培养基上血清饥饿处理24小时。使用浓度不断增加的Rapamycin(0.05-50 nM)在 37oC下处理细胞15分钟。加入血清,终浓度为20%,在37oC下处理30分钟。细胞溶解,使用SDS-PAGE分离细胞裂解液。再溶解的蛋白转移到聚偏(二)氟乙烯膜上,使用抗p70 S6激酶Thr-389的磷酸化的一抗进行免疫印迹。使用ImageQuant 和KaleidaGraph分析数据。
细胞实验:

[6]

+ 展开
  • Cell lines: U87-MG, T98G, 和 U373-MG
  • Concentrations: 溶于DMSO,终浓度为~25 μM
  • Incubation Time: 72 小时
  • Method:

    使用不同浓度Rapamycin处理细胞72小时。为了测量细胞活力,通过胰蛋白酶化收集细胞,使用台酚蓝染色,计数每孔的存活细胞数。为了测定细胞周期, 使细胞胰蛋白酶化,与70%乙醇混合, 使用碘化丙啶染色。使用FACScan流式细胞仪和CellQuest软件分析样本DNA含量。为了测定凋亡, 细胞染色,通过末端脱氧核苷酸转移酶调节的dUTP缺口末端标记法(TUNEL)技术,使用一个ApopTag凋亡检测试剂盒对细胞进行染色。为了测定酸性囊泡细胞器(AVO)的进展,使用吖啶橙(1 μg/mL)对细胞进行染色15分钟,使用荧光显微镜检测。为了量化AVOs的进展,使用吖啶橙(1 μg/mL) 对细胞进行染色15分钟, 然后使用胰蛋白酶-EDTA使其从实验板上移除,最后使用FACScan流式细胞仪和CellQuest 软件分析。为了分析自噬过程,细胞和0.05 mM丹(磺)酰戊二胺(MDC)在37oC下温育10分钟,然后在荧光显微镜下观察。


    (Only for Reference)
动物实验:

[7]

+ 展开
  • Animal Models: 皮下接种表达VEGF-A的C6大鼠胶质瘤细胞的无胸腺Nu/Nu小鼠
  • Formulation: 溶于溶剂溶液(0.2% 羧甲基纤维素和0.25% Tween-80,溶于无菌水)
  • Dosages: ~4 mg/kg/day
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 20 mg/mL (21.87 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 914.18
化学式

C51H79NO13

CAS号 53123-88-9
稳定性 powder
别名 AY 22989,NSC-2260804

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00062712 Completed Kidney Transplantation National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) June 9, 2003 Phase 2
NCT01814059 Terminated Eosinophilic Gastroenteritis|Eosinophilic Esophagitis National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) March 7, 2013 Phase 1
NCT01303965 Active, not recruiting Multiple Myeloma Sherif S. Farag|Celgene Corporation|Indiana University February 7, 2011 Phase 1|Phase 2
NCT02891603 Not yet recruiting Graft Vs Host Disease|GVHD H. Lee Moffitt Cancer Center and Research Institute April 30, 2017 Phase 1|Phase 2
NCT02423915 Recruiting Leukemia|Lymphoma M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Targazyme, Inc.|Cancer Prevention Research Institute of Texas July 30, 2015 Phase 1|Phase 2
NCT01182883 Withdrawn Brain Stem Neoplasms|Glioma|Pinealoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 28, 2010 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

相关mTOR产品

Tags: 购买Rapamycin (Sirolimus) | Rapamycin (Sirolimus)供应商 | 采购Rapamycin (Sirolimus) | Rapamycin (Sirolimus)价格 | Rapamycin (Sirolimus)生产 | 订购Rapamycin (Sirolimus) | Rapamycin (Sirolimus)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID